Rheumatoid arthritis, a rare cause of acute myocarditis: a case report

Mouedder, Fadoua; Ouazzani, Jamal El; Ismaili, Nabila El; Elouafi, Noha

doi:10.11604/pamj-cm.2020.4.115.25381

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 Myocarditis is another rare complication in RA that can contribute to HF. 36 Clinical presentation varies from being asymptomatic to feeling dyspneic to sudden death. Cardiac magnetic resonance imaging (MRI) is a valuable imaging modality in diagnosing myocarditis; however, it does not help in differentiating various causes of myocarditis.…”

Section: Heart Failurementioning

confidence: 99%

Cardiovascular Manifestations in Rheumatoid Arthritis

Sanghavi

Ingressia

Korem

et al. 2022

Cardiology in Review

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a systemic inflammatory disorder that characteristically affects the joints. RA has extra-articular manifestations that can impact multiple organ systems including the heart, lungs, eyes, skin, and brain. Cardiovascular involvement is a leading cause of mortality in RA. Cardiovascular manifestations of RA include accelerated atherosclerosis, heart failure, pericarditis, myocarditis, endocarditis, rheumatoid nodules, and amyloidosis. Inflammation is an important mediator of endothelial dysfunction and is a key driver of cardiovascular risk and complications in patients with RA. Prompt identification of cardiac pathologies in patients with RA is essential for appropriate management and treatment. Choosing the most appropriate treatment regimen is based on individual patient factors. In this article, we provide a comprehensive review of the epidemiology, pathophysiology, clinical manifestations, diagnosis, and medical management of cardiovascular manifestations of RA. We also discuss the relationship between anti-rheumatic medications, specifically non-steroidal anti-inflammatory drugs, corticosteroids, methotrexate, statins, tumor necrosis factor inhibitors, interleukin-6 inhibitors, Janus kinase inhibitors, and cardiovascular disease.

show abstract

Section: Heart Failurementioning

confidence: 99%